Manic after taking a vacation
Emjay Tan, MD

Mr. K, age 36, develops racing thoughts and euphoric mood after returning from a cruise. Mr. K and his wife think his symptoms are caused by a motion-sickness patch. How would you proceed?

CASE  From soft-spoken to manic
Mr. K, age 36, an Asian male with no psychiatric history, arrives at the outpatient psychiatry clinic accompanied by his wife, after being referred from the emergency room the night before. He reports racing thoughts, euphoric mood, increased speech, hypergraphia, elevated self-esteem, decreased need for sleep, distractibility, and increased goal-directed activity. Notably, Mr. K states that he likes how he is feeling.

Mr. K’s wife says that his condition is a clear change from his baseline demeanor: soft-spoken and mild-mannered.

Mr. K reports that his symptoms started approximately 10 days earlier, after he returned from a cruise with his wife. During the cruise, he used a scopolamine patch to prevent motion sickness. Mr. K and his wife say that they believe that the scopolamine patch caused his symptoms.

Can scopolamine cause mania?

a) No
b) Yes; this is well-documented in the literature
c) It is theoretically possible because of scopolamine’s antidepressant and central anticholinergic effects

TREATMENT  Lithium, close follow up
Mr. K has no history of psychiatric illness or substance use and no recent use of psychoactive substances—other than scopolamine—that could trigger a manic episode. His family history is significant for a younger brother who had a single manic episode at age 12 and a suicide attempt as a young adult.

Mr. K works full-time on rotating shifts—including some overnight shifts—as a manufacturing supervisor at a biotechnology company. He has been unable to work since returning from the cruise because of his psychiatric symptoms.

Mr. K is started on sustained-release (SR) lithium, 900 mg/d. In addition, the psychiatrist advises Mr. K to continue taking clonazepam, 0.5 to 1 mg as needed, which the emergency medicine physician prescribed, for insomnia. Mr. K is referred to a psychiatric intensive outpatient program (IOP), 3 days a week for 2 weeks, and is advised to stay home from work until symptoms stabilize.

Mr. K follows up closely with the psychiatrist in the clinic, every 1 to 2 weeks for the first month, as well as by several telephone and e-mail contacts. Lithium SR is titrated to 1,200 mg/d, to a therapeutic serum level of 1.1 mEq/L. Clonazepam is switched to quetiapine, 25 to 50 mg as needed, to address...
ongoing insomnia and to reduce the risk of dependency on clonazepam.

Mr. K’s mania gradually abates. He finishes the IOP and returns to work 3 weeks after his initial presentation. At an office visit, Mr. K’s wife gives the psychiatrist 2 scientific articles documenting the antidepressant effect of scopolamine.1,2 Mr. K and his wife both continue to believe that Mr. K’s manic episode was triggered by the scopolamine patch he used while on the cruise. They think this is important because Mr. K believes he would not have developed mania otherwise, and he does not want to take a mood stabilizer for the rest of his life.

The author’s observations

There are several proposed mechanisms for scopolamine’s antidepressant effect (Table 1).3-9 Scopolamine blocks central muscarinic cholinergic receptors, which reduces production of glutamate receptors and leads to reduced glutamate transmission and neurotoxicity.3,4 Scopolamine—similar to ketamine—could enhance synaptogenesis and synaptic signaling.5,6 Also, by blocking muscarinic autoreceptors, scopolamine results in an acute upregulation of acetylcholine release, which, in turn, influences the nicotinic, dopamine, serotonin, and neuropeptide Y systems. This action could contribute to anti-inflammatory effects, all of which can benefit mood.7,9 These antidepressant mechanisms also could explain why, theoretically, scopolamine could precipitate mania in a person predisposed to mental illness.

Proposed by Janowsky et al10 in 1972, the cholinergic–adrenergic balance hypothesis of affective disorders suggests that depression represents an excess of central cholinergic tone over adrenergic tone, and that mania represents the opposite imbalance. Several lines of evidence in the literature support this theory. For example, depressed patients have been found to have hypersensitive central cholinergic receptors.11,12 Also, central cholinesterase inhibition has been shown to affect pituitary hormone and epinephrine levels via central muscarinic receptors.13 In addition, scopolamine has been shown to attenuate these effects via the central anti-muscarinic mechanism.14

Rapid antidepressant therapy. Scopolamine is being studied as a rapid antidepressant treatment, although it usually is administered via IV infusion, rather than patch form, in trials.15-17 IV ketamine is another therapy being investigated for rapid treatment of depression, which might have downstream mechanisms of action related to scopolamine.5,18 Electroconvulsive therapy is a well-known for its quick antidepressant effect, which could involve synaptogenesis or effects on the neuroendocrine system.19 Sleep deprivation also can produce a rapid antidepressant effect20 (Table 2).2,3,5,6,13,16,18-20.

Clinical Point

The antidepressant mechanisms of scopolamine could explain why, theoretically, it could precipitate mania

Table 1

Theoretical antidepressant mechanisms of scopolamine

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Downregulation of glutamate receptor production</td>
<td>→ decreased glutamate transmission → decreased excitotoxicity3,4</td>
</tr>
<tr>
<td>Enhancement of synaptogenesis, similar to ketamine</td>
<td>→ modulation of nicotinic, serotonergic, and dopaminergic systems</td>
</tr>
<tr>
<td>Upregulation of acetylcholine production</td>
<td>→ modulation of nicotinic, serotonergic, and dopaminergic systems</td>
</tr>
<tr>
<td></td>
<td>→ upregulation of acetylcholine production → modulation of nicotinic, serotonergic, and dopaminergic systems, and an anti-inflammatory effect7-9</td>
</tr>
</tbody>
</table>

NEXT MONTH IN CASES THAT TEST YOUR SKILLS

Ms. K, age 38, is confused, agitated, and endorsing suicidal ideations, symptoms that have worsened over several weeks. Her presentation could indicate a psychiatric condition, but her history is not consistent with a typical course of known psychiatric illness. How would you evaluate her?

Follow this case in the May 2016 issue of Current Psychiatry
**OUTCOME**  Prone to motion sickness

Approximately 3.5 months after his initial presentation, Mr. K continues to do well with treatment. He is euthymic and functioning well at work. He and his wife are preparing for the birth of their first child.

Mr. K is prone to motion sickness, and asks if he can take over-the-counter dimenhydrinate tablets for long car rides. He reports that dimenhydrinate has worked well for him in the past without triggering manic episodes, and he did not anticipate needing to take it very often.

**What would you tell Mr. K about dimenhydrinate for motion sickness during car rides?**

a) Mr. K should not take dimenhydrinate to prevent motion sickness because he experienced a manic episode triggered by a scopolamine patch.

---

**Clinical Point**

Mr. K’s case underscores the role of the muscarinic cholinergic system in regulating mood.

---

**Table 2**

**Rapid antidepressant therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scopolamine²,6,15,16</td>
<td>Research only</td>
</tr>
<tr>
<td>Sleep deprivation¹⁰</td>
<td>Somewhat established; not widely used</td>
</tr>
<tr>
<td>Ketamine⁵,¹⁸</td>
<td>Established; early stages of use</td>
</tr>
<tr>
<td>Electroconvulsive therapy¹⁹</td>
<td>Established; widely utilized</td>
</tr>
</tbody>
</table>

---

**Now online and in print**

**CLINICAL EXPERTS IN BIPOLAR DEPRESSION**

Presentation, Diagnosis, and Treatment

This monthly newsletter series focuses on issues in proper diagnosis and management of adult patients with bipolar disorder. Each of the 3 monthly newsletters reviews a specific challenge and presents a fictional patient case with expert commentary to help healthcare professionals make informed treatment decisions.

Each newsletter features commentary by

Henry A. Nasrallah, MD.

The promotional, non-CME content is intended only for healthcare professionals involved in the treatment of adult patients with bipolar disorder.

©2015 Sunovion Pharmaceuticals Inc. All rights reserved. 11/15 LAT1613-15
Related Resources

Drug Brand Names
Clonazepam • Klonopin
Dimenhydrinate • Dramamine
Ketamine • Ketalar
Lithium • Eskalith, Lithobid
Quetiapine • Seroquel
Scopolamine • Transderm Scop

FOLLOW UP  Cautious use
The psychiatrist advised Mr. K to take dimenhydrinate cautiously when needed for long car rides. The psychiatrist feels this is safe because Mr. K is taking a mood stabilizer (lithium). Also, although dimenhydrinate has anticholinergic properties, occasional use is thought to pose less risk of triggering mania than the constant anticholinergic exposure over several days with a scopolamine patch. (The scopolamine patch contains 1.5 mg of the drug delivered over 3 days [ie, 0.5 mg/d]. In trials of IV scopolamine for depression, the dosage was 0.4 mcg/kg/d administered over 3 consecutive days.15-17 For an adult weighing 70 kg, this would be equivalent to 0.24 mg/d. Therefore, using a scopolamine patch over 3 days would appear to deliver a robust antidepressant-level dosage, even taking into account possible lower bioavailability with transdermal administration compared with IV infusion.)

The psychiatrist concludes that sporadic use of dimenhydrinate tablets for motion sickness during occasional long car rides poses less of a risk for Mr. K of triggering mania than repeat use of a scopolamine patch.

The author’s observations
Mr. K’s case is notable for several reasons:
- Novelty. This might be the first report of scopolamine-induced mania in the literature. In clinical trials by Furey and Drevets,15 Drevets and Furey,16 and Ellis et al,17 no study participants who received scopolamine infusion developed mania or hypomania. Although it is possible that Mr. K’s manic episode could have occurred spontaneously and was coincidental to his scopolamine use, there are valid reasons why scopolamine could trigger mania in a vulnerable person.
- Biochemical insight. The case underscores the role of the muscarinic cholinergic system in regulating mood.10
- Rational medical care. Sensible clinical decision-making was needed when Mr. K asked about using dimenhydrinate for motion sickness during car rides. Although there might not be definitively correct answers for questions that arose during Mr. K’s care (in the absence of research literature), theoretical understanding of the antidepressant effects of anticholinergic medications helped inform the psychiatrist’s responses to Mr. K and his wife.

Bottom Line
Scopolamine, often applied via a transdermal patch to treat motion sickness, has some antidepressant effect, which could lead to mania in a person predisposed to mental illness. The drug’s action on central muscarinic cholinergic receptors could be responsible for its effect on mood. Mood stabilizers and stopping the offending agent are mainstay treatments for scopolamine-induced mania.
References


Clinical Point

Understanding of the antidepressant effects of anticholinergic medications helped inform the psychiatrist’s responses to Mr. K.